|
Apr 8
|
Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024
|
|
Apr 8
|
Sorry, but Blood Tests Won’t Replace Stool Samples or Colonoscopies Yet
|
|
Apr 8
|
Exact Sciences Schedules First Quarter 2024 Earnings Call
|
|
Apr 5
|
The 3 Best Cathie Wood Stocks to Buy in April 2024
|
|
Apr 5
|
Freenome’s colorectal cancer blood test data underwhelm analysts
|
|
Apr 4
|
1 Beaten-Down Cathie Wood Stock to Buy and Hold
|
|
Apr 4
|
Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment
|
|
Apr 3
|
Exact Sciences' (EXAS) Oncoguard Esophagus Test Looks Promising
|
|
Apr 2
|
Exact Sciences, A Cathie Wood Stock, Surges As Rival Colon Cancer Test Pales
|
|
Mar 29
|
Exact Sciences, Mayo Clinic share early data on esophageal cancer test
|
|
Mar 28
|
Ligand (LGND) Down 15.5% Since Last Earnings Report: Can It Rebound?
|
|
Mar 28
|
Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer
|
|
Mar 27
|
Exact Sciences Named 2024 Gallup Exceptional Workplace Award Winner
|
|
Mar 26
|
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
|
|
Mar 26
|
3 Growth Stocks to Buy at 52-Week Lows in March
|
|
Mar 25
|
How Much Upside is Left in Exact Sciences (EXAS)? Wall Street Analysts Think 53.83%
|
|
Mar 25
|
Here's How Much You'd Have If You Invested $1000 in Exact Sciences a Decade Ago
|
|
Mar 22
|
Exact Sciences (EXAS) Up 4.2% Since Last Earnings Report: Can It Continue?
|
|
Mar 21
|
Exact Sciences Corporation (NASDAQ:EXAS) is largely controlled by institutional shareholders who own 89% of the company
|
|
Mar 18
|
Exact Sciences' (EXAS) BLUE-C Study Results Published in NEJM
|